Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 13758.77 Crore) operating in Pharmaceuticals sector.
Ajanta Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Export Incentives and Other Operating Revenue for the year ending 31-Mar-2021.
For the quarter ended 31-03-2022, the company reported a Consolidated Total Income of Rs 899.77 Crore, up 4.39 % from last quarter Total Income of Rs 861.94 Crore and up 18.49 % from last year same quarter Total Income of Rs 759.37 Crore. Company reported net profit after tax of Rs 151.21 Crore in latest quarter.
The brokerage believes AJP will sustain outperformance in the branded generics segment of DF/Africa/Asia aided by new launches, market share gains in existing products and price hikes to some extent. While the near-term outlook would be subdued, the higher pace of filings/approvals would improve the growth prospects in the US generics segment.
Promoters held 70.48 per cent stake in the company as of 31-Mar-2022, while FIIs owned 8.64 per cent, DIIs 12.28 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.